$0.9027
-0.04-4.05%
At close: -
$0.9200
0.021.92%
After Hours: 4:44 PM EDT
Comments
Loading...
Fate Therapeutics Insider Trading Activity | NASDAQ:FATE | Benzinga
Track the latest Fate Therapeutics insider trading activity. Stay informed on recent buys, sells, and market impact for Fate Therapeutics stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Fate Therapeutics Inc Insiders Doing?
Insiders have report no purchases/sales in the last 30 days.
Notable Recent Insider Buys and Sales
- On January 13, 2025, Cindy Tahl, the company's SEE REMARKS sold 5.65K shares for $1.55 each.
- On January 13, 2025, Charles Jerome Bressi, the company's SEE REMARKS sold 5.98K shares for $1.55 each.
- On January 13, 2025, Bahram Valamehr, the company's PRESIDENT AND CEO sold 8.71K shares for $1.54 each.
Ownership Statistics for Fate Therapeutics Inc
Shares Outstanding
113.894M
Insider Shares Owned
2.452M
Insider Percentage Owned
2.15%
Institutional Shares Held
39.840M
Institutional Percentage Held
34.8%
| Jan 13, 2025 | Charles Jerome Bressi | SEE REMARKS | -5.98K | $1.55 | -$9.27K | SELL | -2.17% | 270.20K | Jan 10 | View |
| Jan 13, 2025 | Cindy Tahl | SEE REMARKS | -5.65K | $1.55 | -$8.76K | SELL | -1.65% | 336.71K | Jan 10 | View |
| Jan 13, 2025 | Bahram Valamehr | PRESIDENT AND CEO | -8.71K | $1.54 | -$13.41K | SELL | -2.43% | 349.36K | Jan 10 | View |
| Dec 26, 2024 | Redmile Group LLCJeremy Green | DIRECTOR | 56.33K | $1.68 | $94.64K | BUY | 0.44% | 12.88M | Dec 20 | View |
| Aug 07, 2024 | Yuan Xu | — | -633.00 | $4.23 | -$2.68K | SELL | -6.80% | 8.67K | Aug 06 | View |
| Mar 05, 2024 | Edward Dulac III | CHIEF FINANCIAL OFFICER | -2.45K | $7.77 | -$19.01K | SELL | -2.35% | 101.48K | Mar 04 | View |
| Jan 30, 2024 | Edward Dulac III | CHIEF FINANCIAL OFFICER | -1.85K | $5.00 | -$9.24K | SELL | -1.75% | 103.93K | Jan 29 | View |
| Jan 10, 2024 | Cindy Tahl | GENERAL COUNSEL AND SECRETARY | -10.87K | $4.37 | -$47.52K | SELL | -7.10% | 142.36K | Jan 09 | View |
| Jan 10, 2024 | Bahram Valamehr | CHIEF R&D OFFICER | -11.27K | $4.38 | -$49.37K | SELL | -6.66% | 158.07K | Jan 09 | View |
| Jan 10, 2024 | Scott Wolchko | PRESIDENT AND CEO | -14.39K | $4.37 | -$62.89K | SELL | -3.73% | 371.25K | Jan 09 | View |
| Jan 10, 2024 | Edward Dulac III | CHIEF FINANCIAL OFFICER | -7.03K | $4.37 | -$30.71K | SELL | -6.23% | 105.78K | Jan 09 | View |
| Jan 03, 2024 | Edward Dulac III | CHIEF FINANCIAL OFFICER | -5.18K | $3.66 | -$18.97K | SELL | -4.39% | 112.80K | Jan 02 | View |
| Dec 28, 2023 | Redmile Group LLCJeremy Green | DIRECTOR | 44.63K | $3.72 | $166.02K | BUY | 0.34% | 13.18M | Dec 26 | View |
| Dec 19, 2023 | Edward Dulac III | CHIEF FINANCIAL OFFICER | -1.58K | $3.50 | -$5.55K | SELL | -1.33% | 117.98K | Dec 18 | View |
| Nov 13, 2023 | Cindy Tahl | GENERAL COUNSEL AND SECRETARY | -24.36K | $2.40 | -$58.47K | SELL | -13.72% | 153.24K | Nov 09 | View |
| Aug 21, 2023 | Edward Dulac III | CHIEF FINANCIAL OFFICER | -4.72K | $2.80 | -$13.21K | SELL | -3.80% | 119.57K | Aug 18 | View |
| Aug 07, 2023 | Yuan Xu | DIRECTOR | -632.00 | $3.71 | -$2.34K | SELL | -6.36% | 9.30K | Aug 04 | View |
| Jul 06, 2023 | Brian Powl | CHIEF COMMERCIAL OFFICER | -3.85K | $4.87 | -$18.77K | SELL | -8.56% | 41.15K | Jul 05 | View |
| Jul 06, 2023 | Edward Dulac III | CHIEF FINANCIAL OFFICER | -5.18K | $4.83 | -$25.03K | SELL | -4.00% | 124.29K | Jul 05 | View |
| Jun 15, 2023 | Yuan Xu | DIRECTOR | -3.46K | $5.58 | -$19.31K | SELL | -25.83% | 9.93K | Jun 14 | View |
| Apr 21, 2023 | Redmile Group LLCJeremy Green | DIRECTOR | 276.64K | $6.17 | $1.71M | BUY | 2.15% | 13.14M | Apr 20 - Apr 21 | View |
| Apr 19, 2023 | YuWaye Chu | CHIEF MEDICAL OFFICER | -2.53K | $6.57 | -$16.65K | SELL | -1.77% | 140.68K | Apr 18 | View |
| Apr 17, 2023 | Redmile Group LLCJeremy Green | DIRECTOR | -109.43K | $5.84 | -$1.61M | SELL | -0.84% | 12.86M | Apr 13 - Apr 14 | View |
| Jan 13, 2023 | JOHN MENDLEIN | DIRECTOR | 124.68K | $5.60 | $698.14K | BUY | 78.87% | 282.77K | Jan 11 - Jan 13 | View |
| Jan 11, 2023 | Scott Wolchko | PRESIDENT AND CEO | -45.91K | $5.24 | -$240.55K | SELL | -10.64% | 385.64K | Jan 10 | View |
| Jan 11, 2023 | Bahram Valamehr | CHIEF R&D OFFICER | -10.92K | $5.24 | -$57.21K | SELL | -6.07% | 168.92K | Jan 10 | View |
| Jan 11, 2023 | Cindy Tahl | GENERAL COUNSEL AND SECRETARY | -11.55K | $5.24 | -$60.54K | SELL | -6.11% | 177.60K | Jan 10 | View |
| Jan 11, 2023 | Mark Plavsic | CHIEF TECHNICAL OFFICER | -3.42K | $5.24 | -$17.91K | SELL | -2.69% | 123.70K | Jan 10 | View |
| Jan 11, 2023 | Edward Dulac III | CHIEF FINANCIAL OFFICER | -7.33K | $5.24 | -$38.41K | SELL | -5.36% | 129.47K | Jan 10 | View |
| Jan 11, 2023 | YuWaye Chu | CHIEF MEDICAL OFFICER | -7.83K | $5.24 | -$41.00K | SELL | -5.18% | 143.21K | Jan 10 | View |
| Aug 19, 2022 | Edward Dulac III | CHIEF FINANCIAL OFFICER | -5.13K | $29.81 | -$153.05K | SELL | -3.62% | 136.80K | Aug 18 | View |
| Jul 25, 2022 | Scott Wolchko | PRESIDENT AND CEO | 0.00 | $17.72 | -$1.09M | SELL-OPTIONS | 0.00% | 431.55K | Jul 21 - Jul 22 | View |
| Jul 08, 2022 | Bahram Valamehr | CHIEF R&D OFFICER | 0.00 | $16.48 | -$471.85K | SELL-OPTIONS | 0.00% | 179.83K | Jul 07 | View |
| Jul 07, 2022 | Bahram Valamehr | CHIEF R&D OFFICER | 0.00 | $16.67 | -$210.18K | SELL-OPTIONS | 0.00% | 179.83K | Jul 06 | View |
| Jul 06, 2022 | Mark Plavsic | CHIEF TECHNICAL OFFICER | -3.72K | $24.61 | -$91.52K | SELL | -2.84% | 127.12K | Jul 05 | View |
| Jun 08, 2022 | Shefali Agarwal | DIRECTOR | -841.00 | $21.89 | -$18.41K | SELL | -31.37% | 1.84K | Jun 07 | View |
| Jun 06, 2022 | JOHN MENDLEIN | DIRECTOR | -1.36K | $22.79 | -$31.09K | SELL | -0.86% | 158.09K | Jun 03 | View |
| Jun 06, 2022 | Karin Jooss | DIRECTOR | -1.48K | $22.82 | -$33.84K | SELL | -55.32% | 1.20K | Jun 03 | View |
| Jun 06, 2022 | ROBERT HERSHBERG | DIRECTOR | -672.00 | $22.75 | -$15.29K | SELL | -25.07% | 2.01K | Jun 03 | View |
| Jun 06, 2022 | TIMOTHY COUGHLIN | DIRECTOR | -1.44K | $22.81 | -$32.82K | SELL | -2.44% | 57.63K | Jun 03 | View |
| Jun 06, 2022 | Shefali Agarwal | DIRECTOR | -807.00 | $22.80 | -$18.40K | SELL | -30.10% | 1.87K | Jun 03 | View |
| Jun 02, 2022 | Cindy Tahl | GENERAL COUNSEL AND SECRETARY | 0.00 | $14.76 | -$410.25K | SELL-OPTIONS | 0.00% | 189.15K | Jun 01 | View |
| Apr 25, 2022 | Scott Wolchko | PRESIDENT AND CEO | 0.00 | $18.80 | -$1.29M | SELL-OPTIONS | 0.00% | 431.55K | Apr 21 - Apr 22 | View |
| Apr 21, 2022 | YuWaye Chu | CHIEF MEDICAL OFFICER | -4.06K | $35.37 | -$143.67K | SELL | -2.62% | 151.03K | Apr 19 | View |
| Apr 04, 2022 | Cindy Tahl | GENERAL COUNSEL AND SECRETARY | 0.00 | $22.04 | -$840.73K | SELL-OPTIONS | 0.00% | 189.15K | Apr 01 | View |
| Mar 15, 2022 | Bahram Valamehr | CHIEF R&D OFFICER | 0.00 | $16.90 | -$708.48K | SELL-OPTIONS | 0.00% | 179.83K | Mar 14 | View |
| Mar 11, 2022 | JOHN MENDLEIN | DIRECTOR | 0.00 | $18.32 | -$1.05M | SELL-OPTIONS | 0.00% | 159.46K | Mar 10 | View |
| Jan 24, 2022 | Scott Wolchko | PRESIDENT AND CEO | 0.00 | $21.19 | -$1.48M | SELL-OPTIONS | 0.00% | 431.55K | Jan 20 - Jan 21 | View |
| Jan 13, 2022 | Scott Wolchko | PRESIDENT AND CEO | -14.57K | $48.68 | -$709.03K | SELL | -3.27% | 431.55K | Jan 11 | View |
| Jan 13, 2022 | Cindy Tahl | GENERAL COUNSEL AND SECRETARY | -5.42K | $48.53 | -$262.97K | SELL | -3.36% | 155.85K | Jan 11 | View |
| Jan 13, 2022 | Bahram Valamehr | CHIEF R&D OFFICER | -4.57K | $48.50 | -$221.66K | SELL | -3.02% | 146.53K | Jan 11 | View |
| Jan 13, 2022 | Edward Dulac III | CHIEF FINANCIAL OFFICER | -1.77K | $48.45 | -$85.76K | SELL | -1.60% | 108.63K | Jan 11 | View |
| Jan 13, 2022 | YuWaye Chu | SENIOR VP CLINICAL DEVELOPMENT | -3.96K | $48.51 | -$192.34K | SELL | -3.15% | 121.79K | Jan 11 | View |
| Jan 12, 2022 | Scott Wolchko | PRESIDENT AND CEO | -34.16K | $46.86 | -$1.60M | SELL | -7.11% | 446.11K | Jan 10 | View |
| Jan 12, 2022 | Cindy Tahl | GENERAL COUNSEL AND SECRETARY | -7.74K | $46.43 | -$359.31K | SELL | -4.58% | 161.27K | Jan 10 | View |
| Jan 12, 2022 | Bahram Valamehr | CHIEF R&D OFFICER | -5.60K | $46.38 | -$259.56K | SELL | -3.57% | 151.10K | Jan 10 | View |
| Jan 04, 2022 | Cindy Tahl | GENERAL COUNSEL AND SECRETARY | 0.00 | $32.94 | -$2.64M | SELL-OPTIONS | 0.00% | 169.01K | Jan 03 | View |
| Dec 21, 2021 | Edward Dulac III | CHIEF FINANCIAL OFFICER | -1.54K | $47.76 | -$445.82K | SELL | -1.38% | 110.40K | Dec 20 | View |
| Dec 14, 2021 | Bahram Valamehr | CHIEF R&D OFFICER | 0.00 | $25.19 | -$1.12M | SELL-OPTIONS | 0.00% | 156.70K | Dec 13 | View |
| Dec 13, 2021 | YuWaye Chu | SENIOR VP CLINICAL DEVELOPMENT | 0.00 | $33.89 | -$263.55K | SELL-OPTIONS | 0.00% | 125.76K | Dec 10 | View |
| Nov 22, 2021 | Scott Wolchko | PRESIDENT AND CEO | 86.47K | $28.49 | -$1.03M | SELL-OPTIONS | 21.96% | 480.27K | Nov 18 - Nov 19 | View |
| Oct 25, 2021 | Scott Wolchko | PRESIDENT AND CEO | 0.00 | $31.22 | -$3.40M | SELL-OPTIONS | 0.00% | 393.79K | Oct 21 - Oct 22 | View |
| Oct 04, 2021 | Cindy Tahl | GENERAL COUNSEL AND SECRETARY | 0.00 | $32.69 | -$2.61M | SELL-OPTIONS | 0.00% | 108.05K | Oct 01 | View |
| Sep 30, 2021 | Edward Dulac III | CHIEF FINANCIAL OFFICER | -2.13K | $49.03 | -$601.45K | SELL | -3.91% | 52.40K | Sep 28 | View |
| Sep 14, 2021 | Bahram Valamehr | CHIEF DEVELOPMENT OFFICER | 0.00 | $34.51 | -$1.59M | SELL-OPTIONS | 0.00% | 95.74K | Sep 13 | View |
| Aug 20, 2021 | Scott Wolchko | PRESIDENT AND CEO | 0.00 | $46.42 | -$1.66M | SELL-OPTIONS | 0.00% | 393.79K | Aug 19 | View |
| Aug 20, 2021 | Edward Dulac III | CHIEF FINANCIAL OFFICER | -3.47K | $88.26 | -$306.60K | SELL | -5.99% | 54.54K | Aug 19 | View |
| Jul 26, 2021 | Scott Wolchko | PRESIDENT AND CEO | 0.00 | $44.55 | -$4.93M | SELL-OPTIONS | 0.00% | 393.79K | Jul 22 - Jul 23 | View |
| Jul 02, 2021 | Cindy Tahl | GENERAL COUNSEL AND SECRETARY | 0.00 | $45.44 | -$4.42M | SELL-OPTIONS | 0.00% | 108.05K | Jul 01 | View |
| Jun 16, 2021 | Bahram Valamehr | CHIEF DEVELOPMENT OFFICER | 0.00 | $46.08 | -$2.16M | SELL-OPTIONS | 0.00% | 95.74K | Jun 14 | View |
| May 24, 2021 | Scott Wolchko | PRESIDENT AND CEO | 0.00 | $41.00 | -$1.45M | SELL-OPTIONS | 0.00% | 393.79K | May 20 | View |
| Apr 26, 2021 | Scott Wolchko | PRESIDENT AND CEO | 0.00 | $44.63 | -$4.89M | SELL-OPTIONS | 0.00% | 393.79K | Apr 22 - Apr 23 | View |
| Apr 20, 2021 | YuWaye Chu | SENIOR VP CLINICAL DEVELOPMENT | -3.27K | $83.30 | -$272.81K | SELL | -4.81% | 64.80K | Apr 16 | View |
| Apr 02, 2021 | Cindy Tahl | SEE REMARKS | 0.00 | $43.51 | -$2.42M | SELL-OPTIONS | 0.00% | 108.05K | Apr 01 | View |
| Mar 16, 2021 | Bahram Valamehr | CHIEF DEVELOPMENT OFFICER | -50.00K | $47.63 | -$2.38M | SELL | -34.31% | 95.74K | Mar 15 | View |
| Mar 09, 2021 | Daniel Shoemaker | CHIEF SCIENTIFIC OFFICER | -25.00K | $81.74 | -$2.04M | SELL | -25.50% | 73.02K | Mar 08 | View |
| Feb 19, 2021 | Scott Wolchko | PRESIDENT AND CEO | 0.00 | $54.32 | -$1.91M | SELL-OPTIONS | 0.00% | 393.79K | Feb 18 | View |
| Jan 22, 2021 | Scott Wolchko | PRESIDENT AND CEO | 43.23K | $52.35 | -$5.80M | SELL-OPTIONS | 12.33% | 393.79K | Jan 20 - Jan 22 | View |
| Jan 21, 2021 | Cindy Tahl | GENERAL COUNSEL AND SECRETARY | 0.00 | $58.83 | -$3.92M | SELL-OPTIONS | 0.00% | 90.03K | Jan 19 | View |
| Jan 12, 2021 | Scott Wolchko | PRESIDENT AND CEO | -69.41K | $116.33 | -$8.07M | SELL | -16.53% | 350.56K | Jan 08 - Jan 11 | View |
| Jan 12, 2021 | Bahram Valamehr | CHIEF DEVELOPMENT OFFICER | -9.48K | $114.95 | -$1.09M | SELL | -10.87% | 77.73K | Jan 08 - Jan 11 | View |
| Jan 12, 2021 | Cindy Tahl | GENERAL COUNSEL AND SECRETARY | -9.48K | $114.94 | -$1.09M | SELL | -9.53% | 90.03K | Jan 08 - Jan 11 | View |
| Jan 12, 2021 | Daniel Shoemaker | CHIEF SCIENTIFIC OFFICER | -9.48K | $114.95 | -$1.09M | SELL | -10.19% | 83.61K | Jan 08 - Jan 11 | View |
| Jan 12, 2021 | Redmile Group LLCJeremy Green | DIRECTOR | 327.49K | $85.50 | $28.00M | BUY | 2.59% | 12.96M | Jan 08 | View |
| Dec 18, 2020 | Scott Wolchko | — | 0.00 | $49.22 | -$1.70M | OPTION EXERCISE | 0.00% | 419.97K | Dec 17 | View |
| Dec 15, 2020 | Bahram Valamehr | — | 0.00 | $50.34 | -$2.37M | OPTION EXERCISE | 0.00% | 87.21K | Dec 14 | View |
| Nov 16, 2020 | Daniel Shoemaker | — | -25.00K | $51.83 | -$1.30M | SELL | -21.17% | 93.09K | Nov 16 | View |
| Nov 16, 2020 | Scott Wolchko | — | 0.00 | $28.05 | -$2.86M | OPTION EXERCISE | 0.00% | 419.97K | Nov 12 - Nov 13 | View |
| Nov 06, 2020 | Cindy Tahl | — | 0.00 | $26.61 | -$3.38M | OPTION EXERCISE | 0.00% | 99.52K | Nov 04 - Nov 05 | View |
| Oct 20, 2020 | Cindy Tahl | — | 0.00 | $26.49 | -$1.39M | OPTION EXERCISE | 0.00% | 99.52K | Oct 16 | View |
| Oct 02, 2020 | Cindy Tahl | — | 0.00 | $21.74 | -$1.33M | OPTION EXERCISE | 0.00% | 99.52K | Oct 01 | View |
| Sep 16, 2020 | Bahram Valamehr | — | 0.00 | $19.52 | -$838.25K | OPTION EXERCISE | 0.00% | 87.21K | Sep 14 | View |
| Sep 16, 2020 | Daniel Shoemaker | — | -25.00K | $36.30 | -$907.54K | SELL | -17.47% | 118.09K | Sep 14 | View |
| Jun 17, 2020 | Redmile Group LLCJeremy Green | — | 1.41M | $28.31 | $40.00M | PURCHASE | 12.60% | 12.63M | Jun 11 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.